FDA OK's Trial of CoGenesys' Heart Drug
Posted on: Thursday, 13 July 2006, 12:00 CDT
CoGenesys said Thursday the U.S. Food and Drug Administration has OK'd a phase 1/2 study of Cardeva, a potential drug for heart failure.
The study, which will begin soon, will involve 80 stable patients with class 2 or 3 heart failure. The subjects will receive one or two doses of Cardeva, a long-acting form of b-type natriuretic peptide, or BNP.
BNP stimulates cyclic GMP, which is not only a vasodilator but an inhibitor of the progressive heart muscle structural remodeling that leads to progression of heart failure, Dr. Jay N. Cohn, professor of medicine at the University of Minnesota, said in a statement released by CoGenesys. Chronic administration of a long-acting BNP could have remarkably favorable effects that must be documented in clinical trials, Cohn added.
Heart failure patients with significant decompensation are currently only able to receive a short-acting BNP intravenously, usually in a hospital setting, to improve their clinical status, said Dr. Martha A. Reitman, CoGenesys' senior vice president of medical affairs. With Cardeva, our goal is to provide a low-dose, subcutaneous administration allowing for chronic outpatient treatment that will improve quality of life and decrease the incidence of acute decompensation and hospitalization.
Source: United Press International
Related Articles
- Response Biomedical Receives US FDA Clearance for RAMP(R) NT-proBNP Test for Diagnosis of Heart Failure
- Examine Successful Management of Heart Failure Patients: The Multidisciplinary Approach to Reducing Readmissions
- Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. And Proceed With the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure
- Response Biomedical Announces First Commercial Sales of RAMP NT-proBNP Test for Diagnosis of Congestive Heart Failure
- CoGenesys Initiates Phase 1-2 Clinical Trial of Cardeva in Patients With Heart Failure
- St. Jude Medical Announces FDA Approval of Epic II ICD and Epic II Heart Failure Devices
- Research Suggests That Cardiac Marker NT-proBNP is a Better Predictor for Mortality Than BNP in Heart Failure Patients With Reduced Kidney Function
- NitroMed Presents BiDil(R) Data on Reverse Remodeling in Heart Failure Patients at HFSA Meeting
- FDA Approves AstraZeneca's ATACAND(R) (Candesartan Cilexetil) for Use With an ACE Inhibitor in the Treatment of Heart Failure
- N-Terminal Pro-B-Type Natriuretic Peptide As an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison With Patients in Different Stages of Heart Failure
 |
 |
User Comments (0)
RSS Feeds